NCT04692285 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Kapogiannis D, Wassermann EM
Transcranial magnetic stimulation in Clinical Pharmacology. Cent Nerv Syst Agents Med Chem. 2008 Dec;8(4):234-240. doi: 10.2174/187152408786848076.
Lehericy S, Tijssen MA, Vidailhet M, Kaji R, Meunier S
The anatomical basis of dystonia: current view using neuroimaging. Mov Disord. 2013 Jun 15;28(7):944-57. doi: 10.1002/mds.25527.
Quartarone A, Hallett M
Emerging concepts in the physiological basis of dystonia. Mov Disord. 2013 Jun 15;28(7):958-67. doi: 10.1002/mds.25532.
Thenganatt MA, Jankovic J
Treatment of dystonia. Neurotherapeutics. 2014 Jan;11(1):139-52. doi: 10.1007/s13311-013-0231-4.

Targeting New Receptors in Dystonia: Electrophysiological and Neuroimaging Correlates of the Effect of Zolpidem, a Selective Agonist of Benzodiazepine Subtype Receptor alfa1, in Different Forms of Primary Focal Dystonia

Details for clinical trial NCT04692285

Clinical trial NCT04692285 - References